Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome.

Morgan Prestwich first started building out the Soleno US team as they moved through the clinic and into launching their first asset. After a successful partnership in the US, Morgan Prestwich were retained under Master Service Agreement (MSA) to build their European launch team. With their Head office in Dublin, Ireland - the company are looking to build out the EU5 and beyond - to December 2025 we have covered the following positions.

EU above-country team - Dublin:
- Head of Medical Europe
- Head of Regulatory Europe
- Head of Market Access Europe
- Head of Marketing Europe

German Affiliate:
- Head of Commercial Germany
- 3 xMSL's